Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 816

1.

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program.

Shortridge D, Pfaller MA, Streit JM, Flamm RK.

J Glob Antimicrob Resist. 2019 Oct 21. pii: S2213-7165(19)30263-2. doi: 10.1016/j.jgar.2019.10.009. [Epub ahead of print]

PMID:
31648032
2.

Analysis of Global Antifungal Surveillance Results Reveals Predominance of Erg11 Y132F Alteration among Azole-Resistant Candida parapsilosis and Candida tropicalis and Country-Specific Isolate Dissemination.

Castanheira M, Deshpande LM, Messer SA, Rhomberg PR, Pfaller MA.

Int J Antimicrob Agents. 2019 Sep 11. pii: S0924-8579(19)30246-8. doi: 10.1016/j.ijantimicag.2019.09.003. [Epub ahead of print]

PMID:
31520783
3.
4.

Men Scare Me More: Gender Differences in Social Fear Conditioning in Virtual Reality.

Reichenberger J, Pfaller M, Forster D, Gerczuk J, Shiban Y, Mühlberger A.

Front Psychol. 2019 Jul 18;10:1617. doi: 10.3389/fpsyg.2019.01617. eCollection 2019.

5.
6.

Analysis of Candida auris fungemia at a single facility in Kenya.

Adam RD, Revathi G, Okinda N, Fontaine M, Shah J, Kagotho E, Castanheira M, Pfaller MA, Maina D.

Int J Infect Dis. 2019 Aug;85:182-187. doi: 10.1016/j.ijid.2019.06.001. Epub 2019 Jun 8.

7.

In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017.

Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e00840-19. doi: 10.1128/AAC.00840-19. Print 2019 Aug.

PMID:
31182527
8.

Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015).

Pfaller MA, Sader HS, Shortridge D, Castanheira M, Flamm RK, Mendes RE.

J Chemother. 2019 Jul;31(4):188-194. doi: 10.1080/1120009X.2019.1609740. Epub 2019 May 13.

PMID:
31079589
9.

The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program.

Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00355-19. doi: 10.1128/AAC.00355-19. Print 2019 Jul.

10.

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997-2016.

Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S79-S94. doi: 10.1093/ofid/ofy358. eCollection 2019 Mar.

11.

Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997-2016.

Pfaller MA, Cormican M, Flamm RK, Mendes RE, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S54-S62. doi: 10.1093/ofid/ofy344. eCollection 2019 Mar.

12.

Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program.

Diekema DJ, Pfaller MA, Shortridge D, Zervos M, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S47-S53. doi: 10.1093/ofid/ofy270. eCollection 2019 Mar. Erratum in: Open Forum Infect Dis. 2019 May 20;6(5):ofz202. Zervos, Marcos [corrected to Zervos, Marcus].

13.

Automatic mapping of atrial fiber orientations for patient-specific modeling of cardiac electromechanics using image registration.

Hoermann JM, Pfaller MR, Avena L, Bertoglio C, Wall WA.

Int J Numer Method Biomed Eng. 2019 Jun;35(6):e3190. doi: 10.1002/cnm.3190. Epub 2019 Mar 14.

14.

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.

Huband MD, Pfaller MA, Shortridge D, Flamm RK.

J Glob Antimicrob Resist. 2019 Feb 27;19:56-63. doi: 10.1016/j.jgar.2019.02.017. [Epub ahead of print]

PMID:
30825698
15.

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).

Pfaller MA, Flamm RK, Duncan LR, Shortridge D, Smart JI, Hamed KA, Mendes RE, Sader HS.

Diagn Microbiol Infect Dis. 2019 Jul;94(3):304-313. doi: 10.1016/j.diagmicrobio.2019.01.015. Epub 2019 Jan 26.

PMID:
30808530
16.

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.

Sader HS, Mendes RE, Pfaller MA, Flamm RK.

J Antimicrob Chemother. 2019 May 1;74(5):1306-1310. doi: 10.1093/jac/dkz006.

PMID:
30753485
17.

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.

Shortridge D, Duncan LR, Pfaller MA, Flamm RK.

Int J Antimicrob Agents. 2019 May;53(5):637-643. doi: 10.1016/j.ijantimicag.2019.01.015. Epub 2019 Feb 1.

PMID:
30716448
18.

In Vitro Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015) in the United States.

Pfaller MA, Sader HS, Rhomberg PR, Flamm RK, Mendes RE.

Microb Drug Resist. 2019 Jul/Aug;25(6):938-943. doi: 10.1089/mdr.2018.0410. Epub 2019 Jan 29.

PMID:
30694735
19.

The importance of the pericardium for cardiac biomechanics: from physiology to computational modeling.

Pfaller MR, Hörmann JM, Weigl M, Nagler A, Chabiniok R, Bertoglio C, Wall WA.

Biomech Model Mechanobiol. 2019 Apr;18(2):503-529. doi: 10.1007/s10237-018-1098-4. Epub 2018 Dec 10.

PMID:
30535650
20.

Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America.

Sader HS, Streit JM, Carvalhaes CG, Huband MD, Pfaller MA.

J Glob Antimicrob Resist. 2019 Jun;17:103-108. doi: 10.1016/j.jgar.2018.11.013. Epub 2018 Nov 17.

PMID:
30458298
21.

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016.

Pfaller MA, Flamm RK, Mendes RE, Streit JM, Smart JI, Hamed KA, Duncan LR, Sader HS.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01566-18. doi: 10.1128/AAC.01566-18. Print 2019 Jan.

22.

In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories.

Pfaller MA, Rhomberg PR, Wiederhold NP, Gibas C, Sanders C, Fan H, Mele J, Kovanda LL, Castanheira M.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01230-18. doi: 10.1128/AAC.01230-18. Print 2018 Oct.

23.

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Van Dijck P, Sjollema J, Cammue BP, Lagrou K, Berman J, d'Enfert C, Andes DR, Arendrup MC, Brakhage AA, Calderone R, Cantón E, Coenye T, Cos P, Cowen LE, Edgerton M, Espinel-Ingroff A, Filler SG, Ghannoum M, Gow NAR, Haas H, Jabra-Rizk MA, Johnson EM, Lockhart SR, Lopez-Ribot JL, Maertens J, Munro CA, Nett JE, Nobile CJ, Pfaller MA, Ramage G, Sanglard D, Sanguinetti M, Spriet I, Verweij PE, Warris A, Wauters J, Yeaman MR, Zaat SAJ, Thevissen K.

Microb Cell. 2018 Jun 14;5(7):300-326. doi: 10.15698/mic2018.07.638. Review.

24.

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.

Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.

J Antimicrob Chemother. 2018 Oct 1;73(10):2748-2756. doi: 10.1093/jac/dky235.

PMID:
29982565
26.

Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone.

Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D, Jones RN.

J Clin Microbiol. 2018 Jul 26;56(8). pii: e00339-18. doi: 10.1128/JCM.00339-18. Print 2018 Aug.

27.

Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.

Pfaller MA, Rhomberg PR, Castanheira M.

Diagn Microbiol Infect Dis. 2018 Sep;92(1):43-45. doi: 10.1016/j.diagmicrobio.2018.04.005. Epub 2018 Apr 13.

PMID:
29735424
28.

Impact of rapid, culture-independent diagnosis of candidaemia and invasive candidiasis in a community health system.

Patch ME, Weisz E, Cubillos A, Estrada SJ, Pfaller MA.

J Antimicrob Chemother. 2018 Mar 1;73(suppl_4):iv27-iv30. doi: 10.1093/jac/dky046.

PMID:
29608750
29.

Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014).

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):179-183. doi: 10.1016/j.diagmicrobio.2018.01.019. Epub 2018 Feb 24.

PMID:
29571839
30.

Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.

Pfaller MA, Sader HS, Flamm RK, Castanheira M, Mendes RE.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):199-204. doi: 10.1016/j.diagmicrobio.2018.01.029. Epub 2018 Feb 3.

PMID:
29567128
31.

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.

Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M.

Int J Antimicrob Agents. 2018 Aug;52(2):144-150. doi: 10.1016/j.ijantimicag.2018.02.021. Epub 2018 Mar 3.

PMID:
29510189
32.

Posaconazole MIC Distributions for Aspergillus fumigatus Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values.

Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Dannaoui E, Garcia-Effron G, Guinea J, Kidd S, Pelaez T, Sanguinetti M, Meletiadis J, Botterel F, Bustamante B, Chen YC, Chakrabarti A, Chowdhary A, Chryssanthou E, Córdoba S, Gonzalez GM, Guarro J, Johnson EM, Kus JV, Lass-Flörl C, Linares-Sicilia MJ, Martín-Mazuelos E, Negri CE, Pfaller MA, Tortorano AM.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01916-17. doi: 10.1128/AAC.01916-17. Print 2018 Apr.

33.

Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).

Pfaller MA, Huband MD, Streit JM, Flamm RK, Sader HS.

Int J Antimicrob Agents. 2018 Jun;51(6):848-853. doi: 10.1016/j.ijantimicag.2018.01.006. Epub 2018 Feb 2.

PMID:
29410368
34.

Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).

Pfaller MA, Flamm RK, Duncan LR, Streit JM, Castanheira M, Sader HS.

Diagn Microbiol Infect Dis. 2018 May;91(1):77-84. doi: 10.1016/j.diagmicrobio.2017.12.020. Epub 2018 Jan 3.

35.

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program.

Pfaller MA, Huband MD, Shortridge D, Flamm RK.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02327-17. doi: 10.1128/AAC.02327-17. Print 2018 Apr.

36.

Erratum for Pfaller et al., "In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014".

Pfaller MA, Sader HS, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02383-17. doi: 10.1128/AAC.02383-17. Print 2018 Feb. No abstract available.

37.

An adaptive hybridizable discontinuous Galerkin approach for cardiac electrophysiology.

Hoermann JM, Bertoglio C, Kronbichler M, Pfaller MR, Chabiniok R, Wall WA.

Int J Numer Method Biomed Eng. 2018 May;34(5):e2959. doi: 10.1002/cnm.2959. Epub 2018 Feb 12.

PMID:
29316340
38.

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16).

Pfaller MA, Sader HS, Castanheira M, Flamm RK, Mendes RE.

J Antimicrob Chemother. 2018 Apr 1;73(4):916-922. doi: 10.1093/jac/dkx485.

PMID:
29294031
39.

Relating experimentally-induced fear to pre-existing phobic fear in the human brain.

Levine SM, Pfaller M, Reichenberger J, Shiban Y, Mühlberger A, Rupprecht R, Schwarzbach JV.

Soc Cogn Affect Neurosci. 2018 Feb 1;13(2):164-172. doi: 10.1093/scan/nsx147.

40.

Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).

Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE.

Int J Antimicrob Agents. 2018 Apr;51(4):608-611. doi: 10.1016/j.ijantimicag.2017.12.011. Epub 2017 Dec 23.

PMID:
29277526
41.

Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.

Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02397-17. doi: 10.1128/AAC.02397-17. Print 2018 Mar.

42.

In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).

Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01555-17. doi: 10.1128/AAC.01555-17. Print 2018 Feb.

43.

Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014).

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Feb;90(2):143-147. doi: 10.1016/j.diagmicrobio.2017.10.010. Epub 2017 Oct 19.

PMID:
29157954
44.

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.

Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01856-17. doi: 10.1128/AAC.01856-17. Print 2018 Jan.

46.
47.

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries.

Pfaller MA, Mendes RE, Streit JM, Hogan PA, Flamm RK.

J Antimicrob Chemother. 2017 Nov 1;72(11):3093-3099. doi: 10.1093/jac/dkx251.

PMID:
28961701
48.

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015).

Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M, Flamm RK.

Braz J Infect Dis. 2017 Nov - Dec;21(6):627-637. doi: 10.1016/j.bjid.2017.06.008. Epub 2017 Sep 21.

49.

Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.

Castanheira M, Deshpande LM, Davis AP, Rhomberg PR, Pfaller MA.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00906-17. doi: 10.1128/AAC.00906-17. Print 2017 Oct.

50.

Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).

Pfaller MA, Mendes RE, Sader HS, Castanheira M, Flamm RK.

J Glob Antimicrob Resist. 2017 Dec;11:4-7. doi: 10.1016/j.jgar.2017.06.003. Epub 2017 Jul 19.

PMID:
28735053

Supplemental Content

Loading ...
Support Center